Sofusa is an innovative platform that creates better approaches to delivering injectable medicine. The idea behind Sofusa, as told by Brian Cooley, its Chief Business Officer, was to reinvent drug delivery by taking drugs with an immunologic mechanism of action and delivering them directly into the lymphatic system.
Injectable drugs have issues around measuring injection volumes and drug viscosity. Drugs injected into lymphatic vessels require a much smaller dose, and may result in significantly better outcomes with fewer side effects. The Sofusa system can also modify drug delivery by altering bolus injections and duration of drug infusion. This allows for optimization of the drug pharmacokinetics with a goal of achieving maximum therapeutic benefit while reducing side effects.
With Sofusa’s new micro-epidermal infusion method of drug delivery, lower doses of drug can be infused by accessing the small capillaries beneath the epidermis, which has a higher surface area for absorption.
Using a transdermal system that feels more like a rough surface on the skin than a needle, the method facilitates efficient drug delivery that takes into account drug amount and concentration.